SLC5A2 and type 2 diabetes mellitus: Postulated mechanisms for the improvement in diastolic function following treatment with empagliflozin in experimental T2DM include potential increases in myocardial ketone metabolism, as use of SGLT2 inhibitors leads to increases in circulating ketones, which are a more efficient fuel than fatty acids (Ferrannini et al., 2016; Lopaschuk and Verma, 2016).